Rajshree Sugars & Chemicals Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 19, 2025, 8:20 pm

Quick Insight

Rajshree Sugars & Chemicals Ltd, with a share price of 40.6 and a market capitalization of 135 Cr., presents a mixed financial picture. While the P/E ratio stands at 16.7, indicating a reasonable valuation, the low ROE of 3.05% and ROCE of 4.42% suggest inefficiencies in capital utilization. The company's OPM at 17% is respectable, but the low profitability, with Net Profit at 8 Cr., raises concerns. Additionally, high borrowings of ₹299Cr and a low ICR of 0.60x indicate financial risk. Shareholder distribution is well-spread, with promoters at 40.65%, FIIs at 0.09%, DIIs at 2.88%, and the public at 56.37%. With a P/BV of 0.65x, investors may seek caution due to the undervalued nature of the stock. In conclusion, Rajshree Sugars & Chemicals Ltd appears to be facing challenges in generating returns and managing its debt levels effectively, warranting a closer look at its operational efficiency and financial leverage.

Competitors of Rajshree Sugars & Chemicals Ltd

All Competitor Stocks of Rajshree Sugars & Chemicals Ltd

Quarterly Result

Last Updated: August 20, 2025, 4:45 am

Below is a detailed analysis of the quarterly data for Rajshree Sugars & Chemicals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 141.00 Cr.. The value appears to be declining and may need further review. It has decreased from 175.00 Cr. (Mar 2025) to 141.00 Cr., marking a decrease of 34.00 Cr..
• For Expenses, as of Jun 2025, the value is 146.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 146.00 Cr..
• For Operating Profit, as of Jun 2025, the value is -5.00 Cr.. The value appears to be declining and may need further review. It has decreased from 29.00 Cr. (Mar 2025) to -5.00 Cr., marking a decrease of 34.00 Cr..
• For OPM %, as of Jun 2025, the value is -4.00%. The value appears to be declining and may need further review. It has decreased from 17.00% (Mar 2025) to -4.00%, marking a decrease of 21.00%.
• For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 1.00 Cr..
• For Interest, as of Jun 2025, the value is 3.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 9.00 Cr. (Mar 2025) to 3.00 Cr., marking a decrease of 6.00 Cr..
• For Depreciation, as of Jun 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 6.00 Cr..
• For Profit before tax, as of Jun 2025, the value is -14.00 Cr.. The value appears to be declining and may need further review. It has decreased from 15.00 Cr. (Mar 2025) to -14.00 Cr., marking a decrease of 29.00 Cr..
• For Tax %, as of Jun 2025, the value is 0.00%. The value appears to be improving (decreasing) as expected. It has decreased from 20.00% (Mar 2025) to 0.00%, marking a decrease of 20.00%.
• For Net Profit, as of Jun 2025, the value is -14.00 Cr.. The value appears to be declining and may need further review. It has decreased from 12.00 Cr. (Mar 2025) to -14.00 Cr., marking a decrease of 26.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is -4.27. The value appears to be declining and may need further review. It has decreased from 3.58 (Mar 2025) to -4.27, marking a decrease of 7.85.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 4:21 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 2:29 pm

Below is a detailed analysis of the balance sheet data for Rajshree Sugars & Chemicals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 33.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 33.00 Cr..
• For Reserves, as of Mar 2025, the value is 231.00 Cr.. The value appears to be declining and may need further review. It has decreased from 232.00 Cr. (Mar 2024) to 231.00 Cr., marking a decrease of 1.00 Cr..
• For Borrowings, as of Mar 2025, the value is 299.00 Cr.. The value appears to be improving (decreasing). However, Borrowings exceed Reserves, which may signal higher financial risk. It has decreased from 393.00 Cr. (Mar 2024) to 299.00 Cr., marking a decrease of 94.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 123.00 Cr.. The value appears to be improving (decreasing). It has decreased from 148.00 Cr. (Mar 2024) to 123.00 Cr., marking a decrease of 25.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 687.00 Cr.. The value appears to be improving (decreasing). It has decreased from 806.00 Cr. (Mar 2024) to 687.00 Cr., marking a decrease of 119.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 524.00 Cr.. The value appears to be declining and may need further review. It has decreased from 569.00 Cr. (Mar 2024) to 524.00 Cr., marking a decrease of 45.00 Cr..
• For CWIP, as of Mar 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 1.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 161.00 Cr.. The value appears to be declining and may need further review. It has decreased from 236.00 Cr. (Mar 2024) to 161.00 Cr., marking a decrease of 75.00 Cr..
• For Total Assets, as of Mar 2025, the value is 687.00 Cr.. The value appears to be declining and may need further review. It has decreased from 806.00 Cr. (Mar 2024) to 687.00 Cr., marking a decrease of 119.00 Cr..

However, the Borrowings (299.00 Cr.) are higher than the Reserves (231.00 Cr.), which may signal higher financial risk.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Key Financial Ratios

After reviewing the key financial ratios for Rajshree Sugars & Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 18, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 17) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 18, the value is 9.42. This value is within the healthy range. It has decreased from 10.56 (Mar 17) to 9.42, marking a decrease of 1.14.
• For Diluted EPS (Rs.), as of Mar 18, the value is 9.42. This value is within the healthy range. It has decreased from 10.56 (Mar 17) to 9.42, marking a decrease of 1.14.
• For Cash EPS (Rs.), as of Mar 18, the value is 18.40. This value is within the healthy range. It has decreased from 19.74 (Mar 17) to 18.40, marking a decrease of 1.34.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 18, the value is 46.73. It has increased from 37.20 (Mar 17) to 46.73, marking an increase of 9.53.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 18, the value is 46.73. It has increased from 37.20 (Mar 17) to 46.73, marking an increase of 9.53.
• For Revenue From Operations / Share (Rs.), as of Mar 18, the value is 196.07. It has decreased from 236.66 (Mar 17) to 196.07, marking a decrease of 40.59.
• For PBDIT / Share (Rs.), as of Mar 18, the value is 12.89. This value is within the healthy range. It has decreased from 51.13 (Mar 17) to 12.89, marking a decrease of 38.24.
• For PBIT / Share (Rs.), as of Mar 18, the value is 3.91. This value is within the healthy range. It has decreased from 41.85 (Mar 17) to 3.91, marking a decrease of 37.94.
• For PBT / Share (Rs.), as of Mar 18, the value is -17.42. This value is below the healthy minimum of 0. It has decreased from 16.28 (Mar 17) to -17.42, marking a decrease of 33.70.
• For Net Profit / Share (Rs.), as of Mar 18, the value is 9.42. This value is within the healthy range. It has decreased from 10.46 (Mar 17) to 9.42, marking a decrease of 1.04.
• For NP After MI And SOA / Share (Rs.), as of Mar 18, the value is 9.42. This value is within the healthy range. It has decreased from 10.46 (Mar 17) to 9.42, marking a decrease of 1.04.
• For PBDIT Margin (%), as of Mar 18, the value is 6.57. This value is below the healthy minimum of 10. It has decreased from 21.60 (Mar 17) to 6.57, marking a decrease of 15.03.
• For PBIT Margin (%), as of Mar 18, the value is 1.99. This value is below the healthy minimum of 10. It has decreased from 17.68 (Mar 17) to 1.99, marking a decrease of 15.69.
• For PBT Margin (%), as of Mar 18, the value is -8.88. This value is below the healthy minimum of 10. It has decreased from 6.88 (Mar 17) to -8.88, marking a decrease of 15.76.
• For Net Profit Margin (%), as of Mar 18, the value is 4.80. This value is below the healthy minimum of 5. It has increased from 4.42 (Mar 17) to 4.80, marking an increase of 0.38.
• For NP After MI And SOA Margin (%), as of Mar 18, the value is 4.80. This value is below the healthy minimum of 8. It has increased from 4.42 (Mar 17) to 4.80, marking an increase of 0.38.
• For Return on Networth / Equity (%), as of Mar 18, the value is 20.15. This value is within the healthy range. It has decreased from 28.12 (Mar 17) to 20.15, marking a decrease of 7.97.
• For Return on Capital Employeed (%), as of Mar 18, the value is 2.64. This value is below the healthy minimum of 10. It has decreased from 25.45 (Mar 17) to 2.64, marking a decrease of 22.81.
• For Return On Assets (%), as of Mar 18, the value is 3.49. This value is below the healthy minimum of 5. It has increased from 2.64 (Mar 17) to 3.49, marking an increase of 0.85.
• For Long Term Debt / Equity (X), as of Mar 18, the value is 2.16. This value exceeds the healthy maximum of 1. It has decreased from 3.36 (Mar 17) to 2.16, marking a decrease of 1.20.
• For Total Debt / Equity (X), as of Mar 18, the value is 2.79. This value exceeds the healthy maximum of 1. It has decreased from 4.73 (Mar 17) to 2.79, marking a decrease of 1.94.
• For Asset Turnover Ratio (%), as of Mar 18, the value is 0.58. It has decreased from 0.65 (Mar 17) to 0.58, marking a decrease of 0.07.
• For Current Ratio (X), as of Mar 18, the value is 0.61. This value is below the healthy minimum of 1.5. It has decreased from 0.84 (Mar 17) to 0.61, marking a decrease of 0.23.
• For Quick Ratio (X), as of Mar 18, the value is 0.20. This value is below the healthy minimum of 1. It has decreased from 0.36 (Mar 17) to 0.20, marking a decrease of 0.16.
• For Inventory Turnover Ratio (X), as of Mar 18, the value is 1.05. This value is below the healthy minimum of 4. It has decreased from 1.61 (Mar 17) to 1.05, marking a decrease of 0.56.
• For Interest Coverage Ratio (X), as of Mar 18, the value is 0.60. This value is below the healthy minimum of 3. It has decreased from 2.00 (Mar 17) to 0.60, marking a decrease of 1.40.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 18, the value is 0.42. This value is below the healthy minimum of 3. It has decreased from 1.42 (Mar 17) to 0.42, marking a decrease of 1.00.
• For Enterprise Value (Cr.), as of Mar 18, the value is 451.53. It has decreased from 614.15 (Mar 17) to 451.53, marking a decrease of 162.62.
• For EV / Net Operating Revenue (X), as of Mar 18, the value is 0.81. This value is below the healthy minimum of 1. It has decreased from 0.92 (Mar 17) to 0.81, marking a decrease of 0.11.
• For EV / EBITDA (X), as of Mar 18, the value is 12.43. This value is within the healthy range. It has increased from 4.26 (Mar 17) to 12.43, marking an increase of 8.17.
• For MarketCap / Net Operating Revenue (X), as of Mar 18, the value is 0.15. This value is below the healthy minimum of 1. It has decreased from 0.26 (Mar 17) to 0.15, marking a decrease of 0.11.
• For Price / BV (X), as of Mar 18, the value is 0.65. This value is below the healthy minimum of 1. It has decreased from 1.67 (Mar 17) to 0.65, marking a decrease of 1.02.
• For Price / Net Operating Revenue (X), as of Mar 18, the value is 0.15. This value is below the healthy minimum of 1. It has decreased from 0.26 (Mar 17) to 0.15, marking a decrease of 0.11.
• For EarningsYield, as of Mar 18, the value is 0.30. This value is below the healthy minimum of 5. It has increased from 0.16 (Mar 17) to 0.30, marking an increase of 0.14.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness